Relationship between Immunological Markers and Short-Term Brain Volume Changes in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Interferon Beta-1a (P3.146)
M. Dwyer,R. Zivadinov,Yazhong Tao,Xin Zhang,C. Kennedy,N. Bergsland,D. Ramasamy,Jacqueline Durfee,D. Hojnacki,B. Weinstock-Guttman,B. Hayward,F. Dangond,S. Markovic-Plese
DOI: https://doi.org/10.1212/wnl.82.10_supplement.p3.146
IF: 9.9
2014-04-08
Neurology
Abstract:Objective: Compare percent brain volume change (PBVC) between patients with relapsing-remitting multiple sclerosis (RRMS) treated over 6 months with thrice-weekly interferon beta-1a subcutaneously (IFN beta-1a SC) and healthy controls (HCs); analyze correlations between immunological markers and short-term volume changes among treated patients.
Background: Chronic RRMS progression is associated with decreased brain volume (atrophy). Over the short term, brain volume may change via inflammation-related hydrodynamic changes, which subside following anti-inflammatory therapy (pseudoatrophy). Responses to such therapy may be influenced by patients’ immunological status before and during treatment.
Design/Methods: This 24-week, two-arm (23 RRMS patients receiving IFN beta-1a SC, 15 HCs) pilot study (NCT01085318) evaluated magnetic resonance imaging (MRI) at baseline and 3 and 6 months, and immunological measures at baseline and 6 months. PBVC using SIENA over 0-3, 3-6 and 0-6 months was assessed within groups using Wilcoxon signed-rank test; differences between RRMS patients and HCs were assessed by Wilcoxon rank-sum test. Spearman correlation coefficients were calculated between PBVC and changes in immunological markers in RRMS patients.
Results: PBVC between baseline and 3 months was -0.95% (standard deviation, 1.712%) among RRMS patients (p=0.03) and 0.24% (standard deviation, 1.068%) in HCs (p=0.36); between-group difference was significant (p=0.02). No significant PBVC was seen with either group over Months 3-6 or 0-6. Decreased percentage of CD4+ T-cells producing interleukin (IL)-17F over Months 0-6 was significantly correlated with reduced brain volume over Months 0-6 (r=0.51; p=0.02) in RRMS patients.
Conclusion: IFN beta-1a SC is associated with reduced brain volume over the first 3 months of treatment, but not over 3-6 months, an effect consistent with treatment-induced pseudoatrophy. Correlation between decreased percentage of CD4+ T-cells producing inflammatory IL-17F and volume reduction is supportive of an early anti-inflammatory therapeutic effect of IFN beta-1a SC.
Study supported by: EMD Serono, Inc., Rockland, MA, a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc, New York, USA. Disclosure: Dr. Dwyer has received personal compensation for activities with EMD Serono and Claret. Dr. Zivadinov has received personal compensation for activities with Teva, Biogen Idec, EMD Serono, Novartis, Claret and Sanofi-Genzyme. Dr. Zivadinov has received research support from Biogen Idec, Teva Pharmaceuticals, Sanofi-Genzyme, Novartis and EMD Serono. Dr. Tao has received personal compensation for activities with EMD Serono. Dr. Zhang has received personal compensation for activities with EMD Serono. Dr. Kennedy has nothing to disclose. Dr. Bergsland has nothing to disclose. Dr. Ramasamy has nothing to disclose. Dr. Durfee has nothing to disclose. Dr. Hojnacki has received personal compensation for activities with EMD Serono. Dr. Weinstock-Guttman has received personal compensation for activities with Biogen Idec, Teva Neuroscience, EMD Serono, Pfizer, Novartis, Genzyme, Sanofi-Aventis Pharmaceuticals, Inc., Mylan, and Acorda Therapeutics. Dr. Weinstock-Guttman has received research support from Biogen Idec, Teva Neuroscience, EMD Serono, Pfizer Inc, Novartis, Acorda, ITN, Questcor, Shire, Genzyme, Sanofi-Aventis Pharmaceuticals, Inc., National Multiple Sclerosis Society, the National Institutes of Health and Aspreva-Roche. Dr. Hayward has received personal compensation for activities with EMD Serono as an employee. Dr. Dangond has received personal compensation for activities with EMD Serono, Inc. Dr. Markovic has received personal compensation for activities with EMD Serono. Dr. Markovic has received research support from EMD Serono, Biogen Idec., and Genzyme Corp.
Medicine